Eur J Prev Cardiol. 2026 Aug 11:zwag413. doi: 10.1093/eurjpc/zwag413. Online ahead of print.
ABSTRACT
Recent European and American dyslipidemia guideline updates mark a relevant shift in preventive cardiology. The 2025 ESC/EAS focused update and the 2026 ACC/AHA guideline share the same biological premise: low-density lipoprotein cholesterol and other apolipoprotein B-containing lipoproteins are causal drivers of atherosclerotic cardiovascular disease, and cardiovascular benefit depends on earlier, deeper, and sustained reduction of atherogenic burden. Their main differences lie in how prevention is organized in clinical practice. The European framework places greater emphasis on the explicit linkage between risk categories, predefined low-density lipoprotein cholesterol goals, and treatment escalation. The American framework gives greater operational weight to lifetime risk, coronary artery calcium, non-high-density lipoprotein cholesterol, apolipoprotein B, lipoprotein(a), treatment burden, and shared decision-making more directly into treatment selection. These differences influence patient classification, treatment intensity, and incorporation of non-statin therapies, particularly in borderline-risk primary prevention, subclinical atherosclerosis, and patients requiring combination therapy beyond statins. At the same time, both documents converge on key principles: reduced tolerance for prolonged exposure to atherogenic lipoproteins, broader use of combination lipid-lowering therapy, earlier intensification after acute coronary syndromes and in very high-risk settings, and selective use of biomarkers and imaging to refine prevention. Together, they offer complementary models of contemporary lipid management.
PMID:42579320 | DOI:10.1093/eurjpc/zwag413